Joanne Mortimer, MD, FACP, FASCO, discusses the practical applications and limitations of circulating tumor DNA (ctDNA) testing in breast cancer, highlighting its role in guiding targeted therapy, ...

Experts urge caution with ctDNA testing in early-stage breast cancer, citing "molecular anxiety" and a lack of clear clinical data on survival outcomes. Although the oncology community is buzzing with ...

Dr. W. Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual disease At the CURE Educated Patient Breast Cancer Summit, held during ...

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories. Knollman explained that at ...

Biomarker-driven prescribing patterns in ESR1mut ER+/HER2- metastatic breast cancer (mBC). Temporal trends in breast cancer case volume, subtypes, and age at diagnosis in Vietnam: An eight-year ...

—Tumor-informed circulating tumor DNA testing was shown to be highly sensitive for monitoring patients with metastatic breast cancer receiving standard-of-care therapy. Circulating tumor DNA (ctDNA) ...

Sportschosun] A blood test may help predict the risk of cancer spread in patients with metastatic breast cancer, according to ...

The U.S. Breast Cancer Liquid Biopsy Market is projected to grow from USD 0.39 Billion in 2025 to USD 0.84 Billion by 2035, ...

For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized ...